Insulet Corp designs, manufactures, and markets proprietary systems that deliver insulin continuously for people with insulin-dependent diabetes. Its core offering is the Omnipod platform, which includes the Omnipod 5 Automated Insulin Delivery System, the Omnipod DASH Insulin Management System, and the Classic Omnipod. Beyond diabetes care, Insulet also manufactures pods for Amgen that are incorporated into the Neulasta Onpro kit, a drug delivery device used to help reduce the risk of infection following chemotherapy.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Insulet's research and development initiatives are focused on enhancing user interaction simplicity, improving outcomes through algorithm advancements, deriving insights from datasets and analytics, and offering user choice in sensor and smartphone integrations. The company is working on improvements to Omnipod 5, including new features and functionality for increased economic value and convenience. In 2025, Insulet Corp launched Omnipod 5 with Dexcom’s G7 CGM sensor in the U.S. and several European countries, integrated with Abbott’s FreeStyle Libre 2 Plus sensor in Australia, and received 510(k) clearance for algorithm enhancements. The company is also developing Omnipod 6 and a fully closed-loop AID system for type 2 diabetes, with significant progress in pivotal studies. It seeks to extract insights and value from its growing datasets and analytics. Additionally, users are provided with the freedom to choose their preferred sensor and smartphone integrations. In FY2025, the company spent US$301.1 million on its R&D activities, which, as a percentage of revenue, stood at 11.1%, and grew 37.1% YoY. As of December 2025, the company had over 1,000 patents in the US and certain other countries, and had more than 700 patent applications pending.